2Heikinheimo 0,Gemzell-Dan.ielsson. K. Emerging indicationsfor the levonorgestrel-releasing intrauterine system ( LNGIUS)[J]. Acta Obstet Gynecol Scand,2012,91 ; 3-9.
3Kim ML, Seong SJ. Clinical applications of levonorgestrelreleasingintrauterine system to gynecologic diseases [J] .Obstet Gynecol S c i,2013,56 ; 67-75.
4Dunselman GA,Vermeulen. N, Becker C, et al. ESHREguideline: management of women, with endometriosis [J].Hum Reprod,2014,29 ; 400-412.
5Maruo T- Laoag-Fernandez JB- Pakarinen. P-et al. Effects ofthe levonorgestrel-releasing intrauterine system on.proliferation, and apoptosis in. the endometrium [J]. HumReprod,2001,16:2103-2108.
6Abou-Setta A M , Houston B, Al-Inany HG, et al.Levonorgestrel-releasing intrauterine device ( LNG-IUD) forsymptomatic endometriosis following surgery[DB]. CochraneDatabase Syst R ev,2013 , (1) : CD005072.
7Lan. S , Ling L , Jianhong Z, et al. Analysis of thelevonorgestrel-releasing intrauterine system in. women, withendometriosis[J]. J lilt Med Res, 2013,41 ; 548-558.
8Cho S , Jung J A , Lee Y , et al. Postoperative levonorgestrel releasing intrauterine system versus oral contraceptives aftergonadotropin-releasing hormone agonist treatment forpreventing endometrioma recurrence [J]. Acta ObstetGynecol Scand,2014,93:38-44.
